On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading
In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading
The Cámara de Diputados of the Chilean Congress has overwhelmingly passed a resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number… Continue Reading
For more information, contact: (U.S.) Andrew Goldman, KEI: email@example.com or +1 (202) 332-2670 (Chile) Luis Villaroel, Innovarte: firstname.lastname@example.org +56 9 9827 9673 Chile FAQ What is happening in Chile with regard to HCV medicines and Xtandi, for prostate cancer? In… Continue Reading
KEI has submitted an amicus brief in support of Respondents in the case of Oil States Energy Services, LLC, v. Greene’s Energy Group, LLC, currently before the Supreme Court. The brief is attached here.
On Wednesday September 27, 2017, Knowledge Ecology International delivered an intervention at the PAHO 29th Pan-American Sanitary Conference during agenda item 8.10 on the Draft Concept Note towards WHO’s 13th General Programme of Work 2019–2023. I delivered the statement on behalf of KEI.
On July 11, 2017, the German Federal Supreme Court announced that it had affirmed the decision of the Federal Patent Court last year to issue a compulsory license allowing Merck to continue selling its HIV drug, raltegravir (marketed as Isentress).
Today at WIPO, KEI hosted a side event to discuss the ability of countries to deny injunctions in patent infringement cases.
On March 31st, KEI joined Prescription Justice, EFF, and Public Citizen at RightsCon 2017 to discuss the issues of sales of medication over the Internet. I was in attendance on KEI’s behalf; Gabe Levitt represented Prescription Justice; Jeremy Malcolm presented for EFF; and Burcu Kilic was there for Public Citizen. It was one of the few panels at RightsCon dedicated to medicines/health.
After the session, the panelists convened to draft an agreement on a series of overarching principles that may help guide policy and shape the conversation.
Today, six Senators, including Sen. Durbin (D-IL), Sen. Sanders (I-VT), Sen. Markey (D-MA), Sen. Brown (D-OH), Sen. Blumenthal (D-CT), and Sen. Angus King (I-ME), sent a letter to Acting Secretary of the Army Robert Speer requesting a public hearing on the proposed exclusive license of a federally-funded Zika vaccine to the French multinational, Sanofi, and saying that “it is imperative that any forthcoming vaccine is accessible and affordable for all, especially given the significant taxpayer investment to date.”